Reata Pharmaceuticals Inc Stock Research

Market Summary

USD88.53+2.84

Market Closed

3.31%

RETA Alerts

8 major insider sales recently.

RETA Stock Price

RETA RSI Chart

RETA Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-10.37

Price/Sales (Trailing)

1.5K

EV/EBITDA

-10.27

Price/Free Cashflow

-15.59

RETA Price/Sales (Trailing)

RETA Profitability

EBT Margin

-14076.08%

Return on Equity

474.77%

Return on Assets

-60.62%

Free Cashflow Yield

-6.42%

RETA Fundamentals

RETA Revenue

Revenue (TTM)

2.2M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

RETA Earnings

Earnings (TTM)

-311.9M

Earnings Y/Y

-0.14%

Earnings Q/Q

-8.23%

Price Action

52 Week Range

18.4795.00

(Low)(High)

Last 7 days

-0.9%

Last 30 days

98.9%

Last 90 days

161.1%

Trailing 12 Months

143.7%

RETA Financial Health

Current Ratio

6.75

RETA Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-8.54

Peers (Alternatives to Reata Pharmaceuticals)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	402.9B	94.9B	-1.71%	-11.01%	22.45	4.24	1.25%	-14.07%
LLY	301.4B	28.5B	4.03%	16.86%	48.26	10.56	0.79%	11.88%
MRK	272.8B	59.3B	-2.02%	35.43%	17.88	4.63	21.72%	11.27%
PFE	225.5B	100.3B	-3.66%	-21.92%	7.19	2.25	23.43%	42.74%
BMY	144.7B	46.2B	-3.01%	-5.06%	22.87	3.14	-0.49%	-9.54%
MID-CAP
PRGO	4.6B	4.5B	-5.71%	-9.25%	-32.73	1.03	7.56%	-104.06%
RETA	3.2B	2.2M	98.90%	143.68%	-10.37	1.5K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-4.21%	13.64%	31.93	2.91	15.09%	13.64%
TLRY	1.6B	602.5M	-7.75%	-62.41%	-2.78	2.67	18.18%	-18.59%
CGC	913.9M	478.9M	-19.31%	-78.37%	-0.29	1.91	-31.50%	-634.70%
INVA	787.4M	285.2M	-5.32%	-41.91%	3.57	2.76	-27.21%	-40.28%
CRON	745.9M	114.5M	-6.67%	-53.88%	-4.42	6.52	27.90%	57.40%
ACRS	542.8M	29.8M	-32.56%	-54.58%	-6.25	18.25	340.05%	4.35%
OCUL	396.8M	51.5M	-13.18%	0.78%	-5.59	7.71	18.32%	-984.05%
ENDP	94.1M	2.3B	-43.99%	-88.43%	-0.03	0.04	-22.53%	-376.66%

Financials for Reata Pharmaceuticals

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-29.6%	2,216,000	3,149,000	10,000,000	11,459,000	11,490,000
Operating Expenses	2.6%	280,250,000	273,228,000	267,687,000	265,291,000	256,198,000
S&GA Expenses	1.4%	109,277,000	107,816,000	106,282,000	103,137,000	99,002,000
R&D Expenses	3.4%	169,843,000	164,236,000	160,181,000	160,916,000	155,993,000
EBITDA	-2.5%	-310,796,000	-303,155,000	-298,089,000	-290,070,000	-
EBITDA Margin	-362.6%	-140	-30.32	-26.01	-25.25	-
Earnings Before Taxes	-0.1%	-311,926,000	-311,535,000	-304,379,000	-304,176,000	-297,836,000
EBT Margin	-42.3%	-140	-98.93	-30.44	-26.54	-25.92
Interest Expenses	NaN%	0.00	0.00	-	-	-
Net Income	0.0%	-311,901,000	-311,784,000	-304,628,000	-303,773,000	-297,386,000
Net Income Margin	-42.2%	-140	-99.01	-30.46	-26.51	-25.88
Free Cahsflow	25.8%	-207,537,000	-279,869,000	-275,826,000	-250,299,000	-237,030,000

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-11.8%	514	584	632	680	735
Current Assets	-10.6%	398	445	491	537	596
Cash Equivalents	32.6%	42.00	32.00	147	532	590
Net PPE	-0.7%	11.00	11.00	11.00	11.00	12.00
Current Liabilities	16.3%	59.00	51.00	46.00	44.00	54.00
Shareholder's Equity	-1554.7%	-65.69	5.00	69.00	128	186
Retained Earnings	-5.8%	-1,567	-1,482	-1,403	-1,329	-1,255
Additional Paid-In Capital	1.0%	1,502	1,487	1,472	1,457	1,442
Accumulated Depreciation	-	15.00	-	-	-	-
Shares Outstanding	0.2%	37.00	36.00	36.00	36.00	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	26.2%	-204	-276	-272	-248	-235
Share Based Compensation	-0.4%	59.00	59.00	58.00	58.00	57.00
Cashflow From Investing	15.0%	-345	-405	-337	-1.42	-1.33
Cashflow From Financing	10.7%	1.00	1.00	1.00	5.00	9.00

Risks for RETA

What is the probability of a big loss on RETA?

100%

Probability that Reata Pharmaceuticals stock will be more than 20% underwater in next one year

89.6%

Probability that Reata Pharmaceuticals stock will be more than 30% underwater in next one year.

80.4%

Probability that Reata Pharmaceuticals stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RETA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for RETA

Cumulative Returns on RETA

34.7%

5-Year Cumulative Returns

-16.1%

3-Year Cumulative Returns

What are the long-term rolling returns for RETA?

FIve years rolling returns for Reata Pharmaceuticals.

Annualized Returns

Which funds bought or sold RETA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	reduced	-3.98	176,946	568,748	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-294,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	added	17.2	107,000	245,000	-%
2023-03-02	OLIVER LAGORE VANVALIN INVESTMENT GROUP	new	-	4,065	4,065	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	250,285	739,285	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-70,000	-	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	unchanged	-	342	342	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	added	224	3,428,750	4,305,750	-%
2023-02-15	Financial Gravity Asset Management, Inc.	reduced	-24.00	15.00	19.00	-%
2023-02-15	JANE STREET GROUP, LLC	new	-	1,961,230	1,961,230	-%

Latest Funds Activity

Are funds buying RETA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own RETA

No. of Funds

RETA Alerts

8 major insider sales recently.

Reata Pharmaceuticals News

Schedule 13G FIlings of Reata Pharmaceuticals

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 07, 2023	perceptive advisors llc	6.5%	2,083,799	SC 13G
Feb 14, 2023	first light asset management, llc	6.79%	2,155,552	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.53%	2,705,656	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	2,501,693	SC 13G/A
Sep 22, 2022	point72 asset management, l.p.	5.2%	1,650,400	SC 13G
Sep 09, 2022	wellington management group llp	4.78%	1,508,638	SC 13G/A
Apr 11, 2022	ecor1 capital, llc	6.3%	1,975,611	SC 13G
Mar 10, 2022	invesco ltd.	1.2%	372,165	SC 13G/A
Feb 10, 2022	invesco ltd.	7.2%	2,280,409	SC 13G/A

RETA Fair Value

Reata Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Reata Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	0.02 -99.98%	0.02 -99.98%	0.03 -99.97%	0.04 -99.95%	0.06 -99.93%
Very High Inflation	- -	- -	- -	- -	- -

Historical Reata Pharmaceuticals Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Reata Pharmaceuticals

View All Filings

Date Filed	Form Type	Document
Mar 15, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 09, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 08, 2023	4	Insider Trading
Mar 07, 2023	4	Insider Trading

Latest Insider Trading transactions for RETA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-13	Bir Dawn Carter	sold	-808,436	86.77	-9,317	chief commercial officer
2023-03-10	Ruff Shamim	sold	-480,610	83.73	-5,740	-
2023-03-10	Ruff Shamim	acquired	198,042	34.5021	5,740	-
2023-03-07	WORTLEY MICHAEL D	sold	-34,966	84.46	-414	chief legal officer
2023-03-07	Bir Dawn Carter	acquired	-	-	41,630	chief commercial officer
2023-03-07	Loewen Andrea	sold	-1,588,140	83.4281	-19,036	svp, global regulatory affairs
2023-03-07	Khan Samina	sold	-330,585	83.46	-3,961	svp, chief medical officer
2023-03-07	Loewen Andrea	acquired	409,800	27.32	15,000	svp, global regulatory affairs
2023-03-07	Anand Bhaskar	sold	-13,955	84.58	-165	svp, chief accounting officer
2023-03-07	Soni Manmeet Singh	sold	-52,680	84.695	-622	coo, cfo and president

About Reata Pharmaceuticals

J. Warren Huff

www.reatapharma.com

350

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaboration revenue
Collaboration revenue	$ 2,216	$ 11,490	$ 9,019
Expenses
Research and development	169,843	155,993	159,080
General and administrative	109,277	99,002	75,128
Depreciation	1,130	1,203	1,136
Total expenses	280,250	256,198	235,344
Other income (expense), net	(33,892)	(53,128)	(43,914)
Loss before taxes on income	(311,926)	(297,836)	(270,239)
Benefit from taxes on income	25	450	22,487
Net loss	$ (311,901)	$ (297,386)	$ (247,752)
Net loss per share — basic	$ (8.54)	$ (8.19)	$ (7.35)
Net loss per share — diluted	$ (8.54)	$ (8.19)	$ (7.35)
Weighted-average number of common shares used in net loss per share — basic	36,517,928	36,321,351	33,709,480
Weighted-average number of common shares used in net loss per share — diluted	36,517,928	36,321,351	33,709,480
License and milestone
Collaboration revenue
Collaboration revenue	$ 1,648	$ 8,040	$ 4,701
Other revenue
Collaboration revenue
Collaboration revenue	$ 568	$ 3,450	$ 4,318

RETA Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 42,312	$ 590,258
Marketable debt securities	345,202	0
Prepaid expenses and other current assets	10,256	6,217
Total current assets	397,770	596,475
Property and equipment, net	11,179	11,604
Operating lease right-of-use assets	105,258	126,777
Other assets	284	160
Total assets	514,491	735,016
Liabilities and stockholders’ equity
Accounts payable	18,706	13,505
Accrued direct research liabilities	13,836	14,249
Other current liabilities	24,267	21,450
Operating lease liabilities, current	2,151	3,142
Deferred revenue	0	1,648
Total current liabilities	58,960	53,994
Operating lease liabilities, noncurrent	117,313	132,891
Liability related to sale of future royalties, net	403,913	362,142
Total noncurrent liabilities	521,226	495,033
Commitments and contingencies
Stockholders’ equity:
Additional paid-in capital	1,501,800	1,441,584
Accumulated deficit	(1,567,532)	(1,255,631)
Total stockholders’ equity	(65,695)	185,989
Total liabilities and stockholders’ equity	514,491	735,016
Common Stock A
Stockholders’ equity:
Common stock value	32	31
Common Stock B
Stockholders’ equity:
Common stock value	$ 5	$ 5